Migliaresi S, Tirri G
Cattedra di Reumatologia, Seconda Università degli Studi di Napoli, Italy.
Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S175-80.
To assess the efficacy of alfa-IFN in HCV-associated type II cryoglobulinemia.
An open trial was carried out on 24 patients with HCV-associated type II mixed cryoglobulinemia using recombinant alfa-IFN (3 MU three times weekly for 12 months). The patients were followed for at least 18 months and visceral involvement was evaluated before and after IFN using a scoring system.
Alfa-IFN treatment had a marked effect on skin and liver involvement, while a moderate response was obtained in relation to the nephropathy and peripheral neuropathy. A significant lowering of the cryocrit and an increase in serum C4 were observed. Eleven out of the 16 patients who responded favourably relapsed within six months. In 3 patients, all complete responders, HCV-RNA became undetectable at the end of treatment.
Alfa-IFN may be regarded as the treatment of choice in HCV-associated type II MC, but further studies are required to clarify the factors associated with the lack of response or the relapses seen in some patients.
评估α-干扰素治疗丙型肝炎病毒（HCV）相关的II型冷球蛋白血症的疗效。
对24例HCV相关的II型混合性冷球蛋白血症患者进行了一项开放性试验，使用重组α-干扰素（300万单位，每周3次，共12个月）。对患者进行了至少18个月的随访，并使用评分系统在干扰素治疗前后评估内脏受累情况。
α-干扰素治疗对皮肤和肝脏受累有显著效果，而对肾病和周围神经病变有中度反应。观察到冷沉淀比容显著降低，血清C4升高。16例反应良好的患者中有11例在6个月内复发。在3例患者中，所有完全缓解者在治疗结束时HCV-RNA检测不到。
α-干扰素可被视为HCV相关II型混合性冷球蛋白血症的治疗选择，但需要进一步研究以阐明与某些患者无反应或复发相关的因素。
